Peptide Trainings

Triple Regulator "Reta"

Next-generation triple hormone agonist with the most powerful weight loss data ever recorded in a clinical trial

Retatrutide is Eli Lilly's experimental triple hormone receptor agonist — and the most powerful weight loss compound ever tested in a large-scale clinical trial. While Ozempic (semaglutide) targets one hormone receptor and Mounjaro (tirzepatide) targets two, retatrutide hits three at once: GLP-1, GIP, and glucagon. That third receptor — glucagon — is the game-changer. It does not just reduce how much you eat; it actively boosts your metabolism and increases the energy your body burns at rest. In the Phase 2 trial, participants lost up to 24% of their body weight over 48 weeks. In the TRIUMPH-4 Phase 3 obesity trial (results announced December 2025), participants on 12 mg weekly lost an average of 28.7% of their body weight — that is 71.2 pounds on an average starting weight of 248 lbs — over 68 weeks. 58% of participants on the highest dose achieved at least 25% weight loss. One in eight reported complete resolution of osteoarthritis knee pain. A separate Phase 3 trial in type 2 diabetes showed 16.8% weight loss (36.6 lbs) in just 40 weeks, with A1C reductions of 1.7–2.0%. Retatrutide is not yet FDA approved — an NDA submission is expected in Q4 2026 with approval projected for late 2027 — but it is already considered the next major leap in metabolic medicine.

Mechanism of action

Retatrutide works through three simultaneous hormone pathways, which is what makes it uniquely powerful. First, it activates GLP-1 receptors in the brain and gut — the same pathway as Ozempic — to suppress appetite, slow gastric emptying, and improve insulin secretion. Second, it activates GIP receptors — the same second pathway as Mounjaro — to enhance insulin sensitivity and fat metabolism. Third, and most importantly, it activates glucagon receptors in the liver and fat tissue. Glucagon is a hormone that normally raises blood sugar and increases energy expenditure. By activating glucagon receptors alongside GLP-1 (which counterbalances the blood sugar effect), retatrutide gets the metabolic boost of glucagon without the blood sugar spike. The result is a compound that reduces how much you eat AND increases how much energy your body burns — a combination no single or dual agonist can match.

Benefits discussed in research

  • TRIUMPH-4 Phase 3 (obesity): 28.7% body weight loss — average 71.2 lbs — over 68 weeks
  • 58% of participants on 12 mg achieved at least 25% weight loss
  • Phase 3 (T2D): 16.8% body weight loss (36.6 lbs) in 40 weeks with A1C drop of 1.7–2.0%
  • Phase 2: up to 24.2% body weight loss over 48 weeks
  • Enhanced energy expenditure via glucagon receptor activation — not just appetite suppression
  • Significant reduction in visceral fat, liver fat (MASLD/MASH potential)
  • Improved cardiovascular markers: triglycerides, blood pressure, LDL-C
  • One in eight participants reported complete resolution of osteoarthritis knee pain
  • Weight loss was still progressing at end of TRIUMPH-4 trial — no plateau observed

Research status

Phase III

Dosing information

For educational and research purposes only. Not medical advice.

typical
4 mg once weekly (Phase 3 mid-dose)
range
1 mg (starting) to 12 mg (highest studied dose)
frequency
Once weekly
route
Subcutaneous injection (abdomen preferred; thighs or upper arms also acceptable)
cycleLength
12–48 weeks (Phase 3 ran 40 weeks)
notes
Phase 3 trial used doses of 4 mg, 8 mg, and 12 mg weekly. Start at 1–2.5 mg once weekly for the first 4 weeks, then titrate up by 0.5 mg increments every 4–6 weeks as tolerated. Slow titration is critical to minimize GI side effects. Not yet FDA approved — currently research use only.

Reconstitution and storage

For an educational calculation using a labeled 12 mg vial and a final volume of 1 mL, the concentration is 12 mg/mL. Check the actual product label and follow qualified professional guidance; this example is not a preparation or treatment instruction.

Lyophilized powder: store in a cool, dry, dark area for up to 1 year. Once reconstituted: refrigerate and use within 45–60 days.

Side effects and safety

  • Nausea (most common, especially during dose titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reactions
  • Constipation
  • Fatigue (mild)

Frequently asked questions

What did the Phase 3 TRIUMPH-4 trial show for Retatrutide?

The TRIUMPH-4 Phase 3 trial, focused on adults with obesity (average starting weight 248 lbs, BMI 40), showed that participants on 12 mg weekly lost an average of 28.7% of their body weight — about 71.2 pounds — over 68 weeks. The 9 mg dose produced 26.4% weight loss. The placebo group lost just 2.1%. 58% of participants on 12 mg achieved at least 25% weight loss, and nearly 24% achieved 35% or more. One in eight participants reported complete resolution of osteoarthritis knee pain. Weight loss was still progressing at the end of the trial with no plateau in sight. A separate Phase 3 trial in type 2 diabetes showed 16.8% weight loss (36.6 lbs) in 40 weeks with A1C reductions of 1.7–2.0%.

How does Retatrutide compare to Semaglutide (Ozempic/Wegovy)?

Semaglutide targets one hormone receptor (GLP-1). Retatrutide targets three simultaneously (GLP-1, GIP, and glucagon). In Phase 2 trials, Retatrutide produced up to 24% body weight loss over 48 weeks, compared to about 15% for semaglutide over a similar period. The addition of glucagon receptor activation is the key difference — it boosts metabolism and energy expenditure in a way semaglutide cannot. Think of it as the next generation of the same class, but with a significantly upgraded engine.

How does Retatrutide compare to Tirzepatide (Mounjaro/Zepbound)?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual agonist targeting GLP-1 and GIP. Retatrutide adds a third receptor — glucagon — on top of those two. Phase 2 data suggests Retatrutide produces greater weight loss than tirzepatide, though head-to-head trials have not yet been completed. Both are from Eli Lilly, and Retatrutide is essentially the next evolution of the tirzepatide platform.

Is Retatrutide FDA approved?

No. As of early 2026, Retatrutide is still in Phase 3 clinical trials and has not received FDA approval. Obesity-specific Phase 3 trial results are expected later in 2026. It is currently available for research use only and requires a prescription in jurisdictions where compounding is permitted.

What is the starting dose for Retatrutide?

Based on Phase 3 trial protocols, start at 1–2.5 mg once weekly for the first 4 weeks. Increase by 0.5 mg increments every 4–6 weeks as tolerated. The Phase 3 trial used doses of 4 mg, 8 mg, and 12 mg weekly as maintenance doses. The abdomen is the preferred injection site for consistent absorption.

What concentration does a 12 mg Retatrutide example yield at a final volume of 1 mL?

For an educational calculation, 12 mg in a final volume of 1 mL equals 12 mg/mL. The calculator can show volume equivalents, but it does not establish a safe or appropriate preparation or dose. Refer to the actual label and qualified professional guidance.

How long can I store reconstituted Retatrutide?

Lyophilized (freeze-dried) powder can be stored in a cool, dry, dark area for up to 1 year. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 45–60 days. Never freeze reconstituted peptide and protect from direct light.

What conditions is Retatrutide being studied for?

Active Phase 3 trials are studying Retatrutide for obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD/NASH). Phase 2 data also showed significant reductions in liver fat content, suggesting potential as a treatment for metabolic-associated steatohepatitis (MASH). Obesity-specific Phase 3 results are expected in late 2026.

Research references

Read the Triple Regulator "Reta" profile

Related peptides

  • Semaglutide

    The breakthrough GLP-1 agonist for sustainable weight loss

  • Cagrilintide

    Long-acting amylin analog with additive weight loss when combined with semaglutide

  • Tesamorelin

    FDA-approved GHRH analog for visceral fat reduction

  • 5-Amino-1MQ

    NNMT inhibitor that promotes fat oxidation inside adipocytes without appetite suppression